Publications by authors named "C Martinez-Chamorro"
Article Synopsis
- Teclistamab is a bispecific antibody approved for treating patients with relapsed/refractory multiple myeloma who have previously undergone multiple treatments, including BCMA-targeted therapies.
- In a clinical study (MajesTEC-1), patients with a median of six prior treatments received weekly doses of teclistamab, resulting in a 52.5% overall response rate with some achieving complete remission.
- The treatment had manageable side effects, with common adverse events including neutropenia and infections, while showing a median overall survival of 15.5 months in heavily pretreated patients.
Article Synopsis
- Doctors are unsure about the best time to start treatment for patients with relapsed/refractory multiple myeloma (RRMM) after they start getting worse again.
- A study looked at two groups, one that started treatment early (when the disease started to show signs) and the other that waited until symptoms got worse.
- The group that waited showed better treatment results, lasting longer without the disease getting worse compared to the group that started treatment early.
Background: CPX-351 is approved for the treatment of therapy related acute myeloid leukemia (t-AML) and AML with myelodysplastic related changes (MRC-AML). The benefits of this treatment over standard chemotherapy has not been addressed in well matched cohorts of real-life patients.
Methods: Retrospective analysis of AML patients treated with CPX-351 as per routine practice.
Mortality rates for COVID-19 have declined over time in the general population, but data in patients with hematologic malignancies are contradictory. We identified independent prognostic factors for COVID-19 severity and survival in unvaccinated patients with hematologic malignancies, compared mortality rates over time and versus non-cancer inpatients, and investigated post COVID-19 condition. Data were analyzed from 1166 consecutive, eligible patients with hematologic malignancies from the population-based HEMATO-MADRID registry, Spain, with COVID-19 prior to vaccination roll-out, stratified into early (February-June 2020; = 769 (66%)) and later (July 2020-February 2021; = 397 (34%)) cohorts.
View Article and Find Full Text PDFIntroduction: Belantamab mafodotin (BM) is a new anti-BCMA antibody-drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP).
Methods: We conducted an observational, retrospective, multicenter study including RRMM patients who received ≥ 1 dose of BM (Nov 2019 to Jun 2021).